DefenCath is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anticoagulant
Chronic kidney disease
— DRUG MONOGRAPHS BY SUBSECTION —
News and Features
Kidneys are the most common organs needed for transplant; end-stage kidney disease rates are expected to increase from 29% to 68% in the US by 2030.
Vafseo is an oral reversible inhibitor of hypoxia-inducible factor (HIF)-prolyl-4-hydroxylases (PH)1, PH2, and PH3.
Decline in eGFR early after tolvaptan administration can be easily measured in routine clinical practice.
The randomized, double-blind, parallel-group, placebo-controlled FLOW trial compared the effects of semaglutide 1mg, a GLP-1 receptor agonist, to placebo as an adjunct to standard of care on kidney outcomes.
DISC-0974 is an investigational monoclonal antibody against hemojuvelin, a bone morphogenetic protein-signaling co-receptor.
Together with previous research, this analysis suggests a new therapeutic approach for treating anemia in the CKD population.
In an unexpected finding, phosphodiesterase inhibitors and sympathomimetics with α- and β-effect were strongly associated with higher AKI risk in this analysis.
The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.
Sibeprenlimab, a IgG2 monoclonal antibody that binds to a proliferation-inducing ligand may treat patients with high-risk IgA nephropathy.
The Agency assessed the risk of severe hypocalcemia in 2 studies and through a review of cases.
Cautious drug prescription and frequent drug monitoring are needed in patients with CKD, especially as kidney function declines, according to investigators.
The US Food and Drug Administration (FDA) approved a wide range of therapies in 2023, including many new molecular entities and biological products. The information below is organized by the month in which the product received approval.
The conversion to regular approval was based on data from an additional 165 patients with biopsy-proven IgAN in the phase 3 NeflgArd trial.
Authors recommend hepatitis C treatment with sofosbuvir-based regimens should be expanded, including to those receiving dialysis.
This investigation is among the first observational studies to examine potassium binder use and hard clinical outcomes.
Reduction in urine albumin-to-creatinine ratio mediated 84 and 37% of the treatment effect on kidney and cardiovascular outcomes.
Greater risks of toxic effects were found at higher methotrexate doses and lower eGFR.
DefenCath is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anticoagulant.
- Loading...
